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In the autoimmune disease multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE), ex-
pansion of pathogenic, myelin-specific Th1 cell populations drives active disease; selectively targeting this process may be the basis
for a new therapeutic approach. Previous studies have hinted at a role for protein arginine methylation in immune responses, in-
cluding T cell–mediated autoimmunity and EAE. However, a conclusive role for the protein arginine methyltransferase (PRMT)
enzymes that catalyze these reactions has been lacking. PRMT5 is the main PRMT responsible for symmetric dimethylation of
arginine residues of histones and other proteins. PRMT5 drives embryonic development and cancer, but its role in T cells, if any,
has not been investigated. In this article, we show that PRMT5 is an important modulator of CD4+ T cell expansion. PRMT5 was
transiently upregulated during maximal proliferation of mouse and human memory Th cells. PRMT5 expression was regulated
upstream by the NF-kB pathway, and it promoted IL-2 production and proliferation. Blocking PRMT5 with novel, highly
selective small molecule PRMT5 inhibitors severely blunted memory Th expansion, with preferential suppression of Th1 cells
over Th2 cells. In vivo, PRMT5 blockade efficiently suppressed recall T cell responses and reduced inflammation in delayed-type
hypersensitivity and clinical disease in EAE mouse models. These data implicate PRMT5 in the regulation of adaptive memory Th
cell responses and suggest that PRMT5 inhibitors may be a novel therapeutic approach for T cell–mediated inflammatory
disease. The Journal of Immunology, 2017, 198: 1439–1451.
M
ultiple sclerosis (MS) is a chronic inflammatory disease
of the CNS that affects 2 million young adults
worldwide (1). MS is driven by myelin-reactive in-
flammatory T cells, resulting in axonal demyelination and dis-
ability (2). The reactivation and expansion of myelin-specific
inflammatory T cells is associated with active MS disease, in-
cluding relapses (3–8). Therefore, drugs that suppress these
processes may prevent or curtail the spread of this devastating
disease.
MS is associated with increased Th1 and Th17 inflammatory
responses (9) and deficient Th2 and regulatory T cell responses
(10). In particular, an imbalance between reciprocal Th1 and Th2
responses was reported to be an important etiologic factor in MS.
Several studies showed that T cells from MS patients favor the
proinflammatory Th1 phenotype as opposed to a Th2 phenotype
(11–13). Furthermore, although myelin-reactive T cells are pre-
sent in healthy individuals, MS patients have increased frequen-
cies of myelin-specific T cells with an activated memory
phenotype (14–16).
Upon re-exposure to Ag, memory T cells multiply quickly,
providing a large army of responding T cells. TCR stimulation
results in the activation of several signaling pathways, including the
Notch, c-Myc, NFAT, ERK, JNK, NF-kB, and mTOR pathways
(17). Nuclear translocation of NFAT, Oct, NF-kB and AP-1
transcription factors activate transcription of the pro-proliferative
cytokine IL-2 (18). In addition, Notch and c-Myc induce T cell
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proliferation (19), whereas the mTOR pathway is essential for
glucose metabolism in proliferating T cells (20). Memory T cells
transition quickly from a nonproliferative resting state to maximal
proliferation 2–4 d after Ag exposure. This is followed by a return
to a resting state 7–10 d later (21). Although this process is es-
sential in the immune response against bacterial and other infec-
tions, memory T cell expansion in response to self-antigens can be
harmful, resulting in excessive inflammation and autoimmunity.
The role, if any, that arginine methylation plays in this process
remains vastly unexplored. However, previous studies provide
some clues for further investigation. A role for methylation in
physiologic immune responses was first suggested by the clinical
signs of a debilitating immunodeficiency observed in adenosine
deaminase (ADA)-deficient patients (22, 23). In ADA-deficient
cells, the accumulation of adenosine and deoxyadenosine inhibits
S-adenosyl methionine (SAM)-dependent methylation reactions
(23, 24). In particular, TCR/CD28-mediated proliferation and
cytokine production are inhibited in ADA-deficient patients (22,
23). Similarly, global methyltransferase inhibitors were shown to
have strong immunosuppressive properties and abrogate T cell–
mediated autoimmunity (25–28). Methylthioadenosine, a naturally
occurring metabolite of SAM, can act as a methylation inhibitor
when present at high concentrations (27). It was recently shown
that alterations in the tumor environment result in high tumoral
methylthioadenosine levels that inhibit protein arginine methyl-
ation and suppress anticancer human T cell responses. Therefore,
accumulating evidence hints that the T cell effects of global
methyltransferase inhibition are due to inhibition of protein argi-
nine methyltransferases (PRMTs) (29, 30). However, conclusive
evidence demonstrating that PRMTs are responsible for T cell
suppression, as well as a specific role for the main symmetric
dimethylation (SDM) enzyme PRMT5, has been lacking.
PRMTs are a family of enzymes that catalyze arginine
methylation of nucleosomal histones on chromatin and other
proteins. Among PRMTs, type I PRMTs (PRMT1–4, PRMT6,
and PRMT8) catalyze asymmetric dimethylation, whereas type
II PRMTs (PRMT5 and PRMT9) catalyze SDM at the v-NH2
of arginine (31). Although PRMT9 can catalyze SDM of certain
substrates, most SDM reactions of histones are catalyzed by
PRMT5 (32). Until recently, PRMT7 was considered a type II
PRMT, but it was reclassified as a monomethylating type III
PRMT (33). The modifications catalyzed by PRMTs play a
crucial role in a variety of cellular processes, from differenti-
ation to signaling and proliferation (34). Among PRMTs,
PRMT5 appears to play a particularly relevant role in the reg-
ulation of cell death and malignant transformation processes in
mouse and humans (35–38). Indeed, PRMT5 is upregulated in
various human lymphoid malignancies (39–41) and solid tu-
mors (42–48), and it promotes cancer cell proliferation and
survival (38, 46, 49, 50). This led to the development of se-
lective PRMT5-inhibiting drugs, such as compound 5 (CMP5)
and EPZ015666, as potential new therapies in cancer (43, 51,
52). Although PRMT5 is clearly involved in tumor growth and
survival, its role in T cell responses and its impact on auto-
immunity are unknown.
In this study, we set out to investigate the role of PRMT5 activity
in the expansion of pathogenic Th1 cells that leads toMS.We found
that transient PRMT5 upregulation in response to TCR engagement
in vitro is conserved in mouse and human memory Th1 and Th2
CD4+ T cells. PRMT5 upregulation in Th1 cells required NF-kB
signaling, and inhibition of PRMT5 activity with PRMT5-
selective inhibitors blunted IL-2 secretion and proliferative re-
sponses of memory Th cells. Interestingly, pathogenic Th1 cells
were more sensitive to PRMT5 inhibition than were benign Th2 or
naive T cells, a desirable immunological profile for MS drugs.
In vivo, treatment with the novel PRMT5 inhibitor HLCL65
suppressed Ag-specific T cell responses and inflammation in the
delayed-type hypersensitivity (DTH) model of inflammation and
the experimental autoimmune encephalomyelitis (EAE) model of
MS. This is the first evidence, to our knowledge, that PRMT5
plays an essential role in pathogenic Th1 cell responses. Further,
we describe novel potent PRMT5-selective inhibitors that may
provide a novel therapeutic strategy for Th1-mediated inflamma-
tory autoimmune disease.
Materials and Methods
Mice
B10.PL (Jackson Laboratory) and myelin basic protein (MBP)Ac1–11–
specific TCR-transgenic (Tg) mice [described by Goverman et al. (53)]
were bred in specific pathogen–free conditions at The Ohio State Uni-
versity Laboratory Animal Resources. C57BL/6 and BALB/c mice were
purchased from Taconic and the Jackson Laboratory, respectively. All
animal procedures were approved under electronic Institutional Animal
Care and Use Committee protocol number 2013A00000151.
Reagents
The PRMT5 inhibitor CMP5 was designed and synthesized at The Ohio
State University as previously described (51). Briefly, the compound was
designed to fit into the PRMT5 enzyme crystal structure, partially covering
the binding pockets for both the methyl group donor, SAM, and the ac-
ceptor protein arginine group. Stock CMP5 was dissolved in DMSO ve-
hicle at a concentration of 100 mM and further diluted to 25 mM in DMSO
for in vitro assays. PRMT5 inhibitor HLCL65 was dissolved in DMSO
vehicle at a concentration of 50 mM and was further diluted for in vitro
assays. Stock Bay 11-7082 (Bay11) was dissolved in DMSO vehicle at a
concentration of 10 mM and was further diluted $1:1000 for in vitro
assays.
HLCL65-binding interaction prediction
The crystal structure of human PRMT5:MEP50 complex (PDB ID: 4GQB)
was used to predict the binding interaction of HLCL65 within the PRMT5
active site. The cocrystallized SAM analog (A9145C) and the histone H4–
derived substrate peptide were deleted from the binding site. The small
molecule ligand HLCL65 was prepared by Maestro (Schro¨dinger). Mo-
lecular docking was accomplished by AutoDock 4. The binding energy of
the protein–ligand interaction in the shown binding mode was 213.14
kcal/mol.
Histone methyltransferase assays
Histone methylation was performed using 2 mg of HeLa S3 core histones in
the presence or absence of 15 ml of affinity-purified human SWItch/sucrose
nonfermentable–associated Flag-tagged PRMT5 or Flag-tagged PRMT7,
as described previously (54). Reaction mixtures were spotted on Whatman
P-81 filter paper and washed five times with 10 ml of 0.1 mm sodium
carbonate buffer (pH 9) to remove unincorporated [3H]SAM, and meth-
ylated peptides were detected by scintillation counting.
Cells
Mouse Th1 and Th2 cell lines were generated from MBP TCR-Tg mice
(53). Naive T cells were isolated from TCR-Tg splenocytes by magnetic
bead sorting using the CD4+CD62L+ T Cell Isolation Kit, mouse (Miltenyi
Biotec) and activated with MBPAc1–11 (0.5 mg/ml) presented by irradiated
splenocytes under Th1 (IL-12 + IFN-g, anti–IL-4) or Th2 (IL-4, anti–IL-12
and anti–IFN-g) conditions for two rounds. Th cell lines are not trans-
formed and, therefore, were maintained by stimulation with MBPAc1–11
and irradiated splenocytes in the presence of rIL-2 every 7–10 d. T cells
collected 7–10 d after activation with MBPAc1–11 and irradiated spleno-
cytes provided the resting Th cell condition. To avoid the presence of non-
T cells in in vitro experiments, resting Th1 or Th2 cell lines were activated
with anti-CD3/CD28 in the presence or absence of the PRMT5 inhibitors
CMP5 or HLCL65 or DMSO as vehicle control for various lengths of time.
Human Th1 and Th2 cells were generated by isolating CD4+ T cells with a
CD4+ T Cell Isolation Kit (STEMCELL Technologies) from human whole
blood leukocytes from normal donors and activating on anti-CD3/CD28
Dynabeads (Thermo Fisher) under Th1 or Th2 conditions (same as mouse)
for 1 wk. Th cells were removed from the Dynabeads and reactivated with
plate-bound anti-CD3 (1 mg/ml for Th1, 5 mg/ml for Th2) and soluble
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CD28 (1 mg/ml for Th1, 2 mg/ml for Th2) for further experiments. Naive
CD4+ T cells were isolated with the mouse naive CD4+ T Cell Isolation Kit
(Miltenyi Biotec) and activated with 5 mg/ml coated anti-CD3 and 2 mg/ml
soluble anti-CD28. CCMCL1 cells are a mantle cell lymphoma cell line
that was described previously (55).
Western blot
Cells were lysed in Passive Lysis Buffer (Promega) or RIPA buffer (10 mM
Tris, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% deoxycholate)
containing protease inhibitors and phosphatase inhibitors (Thermo Fisher).
Protein concentrations were determined using a NanoDrop 2000 or BCA
assay (Thermo Fisher). Equal quantities of protein (5–10 mg) were sepa-
rated on 10–14% SDS-PAGE gels and transferred to nitrocellulose or
polyvinylidene difluoride membranes (162-0177; Bio-Rad). Membranes
were incubated with rabbit anti-PRMT5 Ab (1:500, ab31751; Abcam),
anti-PRMT1 Ab (CST 2449S; Cell Signaling Technology), anti-PRMT7
Ab (ab22110; Abcam), or mouse anti-b-actin Ab (1:20,000, A1978;
Sigma) overnight at 4˚C or for 3 h at room temperature. After incubation
with HRP-conjugated anti-rabbit Ab (1:15,000, A0545) or anti-mouse Ab
(1:20,000, A9044; both from Sigma), Western blots were developed with
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher), and
the luminescent signal was captured on film and developed on a Konica-
Minolta SRX-101A or digitally on a Fuji LAS-4000 Imaging System.
After incubation with fluorescently labeled anti-rabbit or anti-mouse sec-
ondary Abs (Odyssey LI-COR), Western blots were imaged with Odyssey
CLx. The Western blotting bands were analyzed by ImageJ (Bio-Arts,
Fukuoka, Japan) or Image Studio software.
RNA isolation
Total RNAwas isolated with a mirVana kit (Life Technologies), according
to the manufacturer’s instructions, and stored at 280˚C until analysis.
RNA concentration and quality were determined using a NanoDrop 2000.
Real-time PCR
RNA (300–1000 ng) from profiled samples were cDNA transcribed using
random primers and Superscript II (Applied Biosystems); TaqMan quantitative
real-time PCR was performed using mTbx21 (Mm00450960_m1) and mHPRT
(Mm0044968_m1) primer sets (Life Technologies), according to the manu-
facturer’s instructions. Samples were cDNA transcribed using random primers
and Superscript III (Applied Biosystems of similar amplification efficiency for
test and control genes). An initial denaturation step at 95˚C for 10 min was
followed by 40 cycles of denaturation at 95˚C for 15 s and primer annealing/
extension at 60˚C for 60 s. Results were analyzed using the comparative Ct
method.
Cytokine ELISA
Cytokines were detected in supernatants at various points poststimulation
using a sandwich ELISA. Mouse IL-2 reagents were from BD, mouse IL-17
reagents were purchased from eBioscience (Capture: 14-7175-85, Detec-
tion: 13-7177-85), human IL-2 reagents were purchased from BioLegend
(Capture: 500302, Detection: 517605), and recombinant human IL-2 was
purchased from Miltenyi Biotec. ELISA was performed as previously
described (12).
[3H]thymidine proliferation assay
Th1 and Th2 cell lines were plated on anti-CD3/CD28–coated wells
(100,000–125,000 cells per well) and treated with CMP5 inhibitor, or
vehicle control (DMSO), and/or increasing concentrations of IL-2. Two
days after treatment, cells were pulsed with 1 mCi of tritiated thymidine
([3H]thymidine). After 18 h, cells were harvested on a Filtermate 196
harvester, and the amount of [3H]thymidine incorporated into the DNA
was measured using a TopCount microplate scintillation and lumines-
cence counter (both from Packard/Perkin-Elmer, Waltham, MA).
Intracellular flow cytometry
On collection day, cells were treated with PMA/ionomycin and GolgiStop
(BD Biosciences) for 4–6 h and washed with FACS buffer prior to Fc
region blockade and surface Ab staining (10 min, 4˚C). Samples were fixed
with Fixation/Permeabilization buffer and washed with Perm/Wash Buffer
(554715; BD Biosciences). The intracellular proteins T-bet (644807;
BioLegend), IL-17 (506916; BioLegend), and RORgt (12-698880; eBio-
science) were stained with the corresponding Abs (T-bet clone: 4B10, IL-
17 clone: TC11-18H10.1, and RORgt clone: AFKJS-9) for 30 min at 4˚C.
T-bet+RORgt+, IL-17+RORgt+, and T-bet+IL-17+ double-positive pop-
ulations were analyzed within the CD4+CD44+ T cell gate.
Short hairpin RNA lentivirus transfection and transduction
Lentiviral vectors expressing five PRMT5-targeted short hairpin RNAs
(shRNAs; target set RHS4533-EG10419) and the universal negative control,
pLKO.1 (RHS4080), were acquired fromOpen Biosystems. HEK293T cells
(Takara Clontech) were transfected with lentiviral vectors plus DNAvectors
encoding HIV Gag/Pol and VSV-G in 10-cm dishes with Lipofectamine
2000 (Life Technologies), according to the manufacturer’s instructions.
Lentiviral particle–containing supernatant was collected after 72 h, filtered
through 0.45-mm filters, and concentrated using ultracentrifugation in a
Sorvall SW 41 swinging bucket rotor. Human Th1 cells were prepared by
resuspending 500,000 cells in 50 ml of concentrated lentivirus plus 8 mg/ml
Polybrene. Human Th1 cells were transduced by spinoculation at 2000 3 g
for 2 h at room temperature and incubated for 1 h at 37˚C. Virus was washed
out, and cells were plated on anti-CD3/CD28–coated plates for proliferation
or protein.
Small interfering RNA transfection with Neon electroporation
To knockdown PRMT5, we selected three small interfering RNAs (siRNAs)
targeting different areas in the PRMT5 gene. Two siRNAs (si#1: 59-AAT
TCC AAG GTG CAATAG CGG CCT GTC TC-39 and si#2: 59-ACA CUU
CAU AUG UCU GAG A-39) were synthesized in-house with the Silencer
siRNA Construction Kit (AM1620M; Thermo Fisher). The third siRNA
(si#3) was purchased from Ambion (cat. no. s77695). For siRNA trans-
fection, the Neon Transfection System (Invitrogen) was used, following the
manufacturer’s instructions and adapting them as indicated below. Human
Th cells were prepared by washing twice with PBS, removing all of the
supernatant after the last wash. Five million primary T cells were resus-
pended in 100 ml of T buffer containing 1.5 mg of siRNA and electro-
porated (one pulse at 2100 V for 20 ms) using a Neon 100-ml transfection
pipette. Cells were mixed 1:1 with 100 ml of 2% Viability Buffer (a gift
from Dr. R. Han, The Ohio State University) to promote cell viability after
electroporation. Finally, cells were plated into media lacking penicillin/
streptomycin. Proliferation and protein expression were monitored as in-
dicated.
OVA-induced DTH
CFA (Difco) and OVA emulsion was prepared at a 1:1 v/v ratio for a final
concentration of 1500 mg of OVA/1 ml of PBS. BALB/c mice were in-
jected with 100 ml of emulsion in the dorsal proximal scruff and the base
of the tail (150 mg of OVA per mouse). Control groups included non-
immunized mice and immunized mice that were not subsequently chal-
lenged with OVA. One week after immunization, aggregated OVA was
prepared by suspending in PBS at a concentration of 10 mg/ml in a 15-ml
tube. Solution was heated in an 80˚C water bath for 60 min. Mice were
challenged with 300 mg of aggregated OVA by injecting 30 ml of solution
into the left footpad of immunized mice. After an additional week, mice
were rechallenged in the same manner (nonimmunized mice were also
challenged at this step). Twenty-four hours after the second challenge,
mice were euthanized by CO2 asphyxiation and cervical dislocation. Each
footpad was measured using calipers for swelling (pre-euthanasia) and
weighed for changes in mass. Additionally, spleens were removed and
processed for in vitro studies.
Experimental autoimmune encephalomyelitis
For induced EAE, commercial Hooke Reagent or myelin oligodendrocyte
glycoprotein (MOG; CS Bio) and CFA (Difco) emulsion were used.
CFA/MOG emulsion was prepared in a 1:1 v/v ratio for a final con-
centration of 1000 mg MOG/1 ml of PBS. C57/B6 mice (Taconic) re-
ceived 100 ml of emulsion s.c. in the dorsal proximal scruff and the base
of the tail. About 2 h after immunization, mice were injected i.p. with
100 ml of 2 ng/ml pertussis toxin. Twenty-four hours later, mice were
injected again with 100 ml of 2 ng/ml pertussis toxin. Mice were moni-
tored for disease every day and treated with 25 mg/kg HLCL65 or
DMSO vehicle control. At the indicated time points, mice were eutha-
nized by injection with 20 mg/ml ketamine and 4 mg/ml xylazine
(120 ml/20 g mouse) and perfused with PBS. Spleens, brains, and spinal
cords were collected from representative mice and processed for in vitro
studies. To isolate brain and spinal cord mononuclear cells, brains and
spinal cords were processed through a 70-mm strainer and separated by a
70–30% isotonic Percoll gradient.
For spontaneous EAE, three MBPAc1–11 TCR-Tg mice that developed
EAE spontaneously (scores = 1.5–2) were euthanized by CO2 asphyxiation
and cervical dislocation. Splenocytes were isolated and activated with
2 mg/ml MBPAc1–11 for 48 h in the presence of PRMT5 inhibitors or ve-
hicle control. T-bet, IL-17, and RORgt expression was analyzed by in-
tracellular flow cytometry.
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Results
PRMT5 protein is upregulated upon memory T cell reactivation
PRMT5 is overexpressed in several lymphoid malignancies, where
it promotes uncontrolled cell growth and survival of transformed
cells (35). However, its role in nonmalignant memory T cell
proliferative responses is unknown. After exposure to their cog-
nate Ag, previously sensitized T cells activate a signaling cascade
that enhances metabolic activity and drives maximum prolifera-
tion at 2–3 d postactivation. Subsequently, the proliferative rate of
T cells gradually decreases, and cells that survive the contraction
period return to a nonproliferative resting state 7 d after activation
(21). To determine whether PRMT5 plays a role in this process,
PRMT5 expression was analyzed by Western blotting at various
time points after MBPAc1–11 TCR-Tg mouse memory Th1 or Th2
cells (characterized in Supplemental Fig. 1) were restimulated
with immobilized anti-CD3/CD28. Compared with resting mem-
ory T cells, PRMT5 was upregulated 2.5-fold in Th1 cells and
2.4-fold in Th2 cells at the 48-h time point, the peak of PRMT5
expression (Fig. 1A, 1B). PRMT5 was subsequently downregu-
lated at day 4, reaching baseline levels by day 7. These results led
us to hypothesize that PRMT5 promotes proliferation during the
normal cycle of T cell activation.
Selective PRMT5 inhibition blunts TCR-mediated memory
T cell expansion
To determine whether PRMT5 activity is required for memory
T cell proliferation, resting memory Th1 and Th2 T cells were
activated in vitro, and the extent of T cell expansion was measured
by [3H]thymidine-incorporation assay in the presence of the
FIGURE 1. Proliferating murine Th1 and Th2 T cells express increased PRMT5 protein levels. MBP-specific TCR-Tg memory Th1 (A) and Th2 (B) cells
were lysed at resting or at 1, 2, 3, 4, or 7 d after anti-CD3/CD28 stimulation and analyzed for PRMT5 protein expression by Western blotting. Resting cells
were nonproliferating T cells and were collected 7–10 d after activation of the Th cell line with MBPAc1–11 and irradiated splenocytes. b-actin was used as a
loading control. Relative intensity quantification data are shown above a representative blot and were determined by normalizing PRMT5 expression to
b-actin expression using Image Studio. Data are representative of three or four independent experiments (n = 5 for experiment shown). *p , 0.05, **p ,
0.01, ****p , 0.001, one-way ANOVA, followed by the Sidak multiple-comparison adjusted t test. MBP TCR-Tg memory Th1 (C and D) and Th2 (E and
F) cells were stimulated with MBPAc1–11 for 48 h in the presence of the PRMT5 inhibitor CMP5 or vehicle control (DMSO), and proliferation (C and E) and
viability (D and F) were measured by [3H]thymidine incorporation or annexin V staining, respectively. Data are representative of three or four experiments
(n = 4 for shown experiment) and are pooled from two independent experiments (n = 4). ***p , 0.001, Student t test. MBP TCR-Tg memory Th1 and Th2
cells were stimulated with anti-CD3/CD28 for 48 h in the presence of various concentrations of the PRMT5 inhibitors CMP5 (G) or HLCL65 (H) or vehicle
control. Proliferation was monitored via [3H]thymidine incorporation. Data representative of three to four independent experiments (shown experiment
n = 4). Plot error bars show6 SD. *p, 0.05, ***p, 0.001, ****p , 0.001, two-way ANOVA, followed by the Sidak multiple-comparison adjusted t test.
D, dead; EA, early apoptotic; L, live; LA, late apoptotic; N, necrotic.
1442 PRMT5 DRIVES INFLAMMATORY T CELL RESPONSES AND AUTOIMMUNITY
previously described PRMT5 inhibitor, CMP5 (51), or DMSO
vehicle control. CMP5 was designed to selectively and reversibly
bind within the PRMT5 active site to prevent transfer of the
methyl group from the donor, SAM, to the arginine substrate-
binding pocket. CMP5 selectively inhibits PRMT5-mediated
SDM but not other PRMTs (51). Overall, these data indicate
that CMP5 is a selective PRMT5 inhibitor. CMP5 treatment of
mouse Th1 and Th2 cells strongly inhibited T cell proliferation
(Fig. 1C, 1E). A detailed analysis of apoptosis status via annexin
V/propidium iodide staining revealed that there were no signifi-
cant differences in apoptotic or dead cells in cells treated with
PRMT5 inhibitor (Fig. 1D, 1F), indicating that the reduced pro-
liferation could not be explained by cell death. Interestingly, we
noticed a small, but significant, difference in Th1 versus Th2
suppression with CMP5. Th1 cell proliferation was more sensitive
to PRMT5 inhibitors than was Th2 cell proliferation (95.4 versus
90.5% inhibition, respectively, p , 0.005, t test). To further ex-
plore this phenomenon, we analyzed the IC50 values of the
PRMT5 inhibitor CMP5 for both cell types. Indeed, we confirmed
that CMP5 inhibited Th1 cell proliferation (IC50 = 3.7 mM) more
potently than Th2 cell proliferation (IC50 = 9.2 mM) (Fig. 1G,
Table I. IC50 values for PRMT5 inhibitors CMP5 and HLCL65 in
mouse and human Th1 and Th2 cells
Compound Cell Type IC50 (mM) Hill Slope R
2
CMP5 mTh1 3.7 20.8334 0.96
mTh2 9.2 23.174 0.98
hTh1 26.9 23.454 0.94
hTh2 31.6 26.276 0.96
HLCL65 mTh1 1.1 21.392 0.91
mTh2 4 22.321 0.97
hTh1 5.7 23.291 0.98
hTh2 14.3 24.15 0.97
h, human; m, mouse.
FIGURE 2. PRMT5 is essential for human Th1 and Th2 cell expansion. Human CD4+ T cells were isolated from whole blood and differentiated under
Th1- or Th2-inducing conditions. After differentiation, Th1 (A) and Th2 (B) cells were reactivated on anti-CD3/CD28, and cells were lysed at rest and at 1,
2, 3, 4, and 7 d. PRMT5 protein expression was analyzed by Western blotting; b-actin was used as a loading control. Relative intensity quantification data
are shown above a representative blot. Data are representative of three independent experiments (n = 3 for experiment shown). *p, 0.05, **p , 0.01, one-
way ANOVA, followed by the Sidak multiple-comparison adjusted t test. Human memory Th1 (C and D) and Th2 (E and F) T cells were activated with anti-
CD3/CD28 for 48 h in the presence of the PRMT5 inhibitor CMP5 or vehicle control (DMSO), and the extent of T cell expansion (C and E) or viability (D
and F) was measured by [3H]thymidine incorporation or trypan blue exclusion, respectively. Data are representative of three or four experiments (n = 3 for
experiment shown). ***p , 0.001, Student t test. Human memory Th1 and Th2 cells were activated as in (C)–(F) in the presence of varying concentrations
of vehicle control, CMP5 (G), or HLCL65 (H), and T cell proliferation was measured by [3H]thymidine incorporation. Plot error bars show 6 SD. *p ,
0.05, **p , 0.01, ****p , 0.0001, two-way ANOVA, followed by the Sidak multiple-comparison adjusted t test. n.s., not significant.
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Table I). To determine whether this phenomenon was isolated or
could be replicated with CMP5 derivatives, we took advantage of
a second-generation bioavailable PRMT5-selective inhibitor,
HLCL65 (Supplemental Fig. 2A, 2B). HLCL65 selectively
inhibited PRMT5-mediated SDM (Supplemental Fig. 2C, 2D).
HLCL65 inhibited T cell proliferation more potently than CMP5,
and it suppressed Th1 cells (IC50 = 1.1 mM) more effectively than
Th2 cells (IC50 = 4.0 mM) (Fig. 1H, Table I). Overall, these data
indicate that PRMT5 promotes murine memory T cell expansion
and that inflammatory memory Th1 cells are more sensitive to
targeting with PRMT5 inhibitors than are Th2 cells. To determine
whether the proliferation or differentiation of newly activated
naive T cells was similarly dependent on PRMT5 activity, we
treated freshly isolated naive CD4+ T cells with PRMT5 inhibi-
tors. CMP5 and HLCL65 suppressed T cell proliferation in a dose-
dependent manner (Supplemental Fig. 3A, 3B). Interestingly, and
reminiscent of Th2 cells’ behavior, naive CD4+ T cells were
more resistant than memory Th1 cells to PRMT5 inhibitors
(Supplemental Fig. 3A, 3B). We also observed decreased IFN-g in
supernatants from naive T cell cultures differentiated with CMP5
and HLCL65 in the absence of exogenous polarizing signals
(Supplemental Fig. 3C, 3D). Overall, these results show prefer-
ential suppressive effects of PRMT5 inhibitors on memory Th1
responses that drive inflammatory autoimmune diseases, such
as MS.
PRMT5 is essential for human T cell activation and expansion
Targeting of pathogenic Th cell expansion may be beneficial as a
therapy in human Th1–mediated autoimmune diseases. To deter-
mine whether PRMT5 plays a similar role in human T cells, we
restimulated previously differentiated human memory Th1- and
Th2-enriched cells from healthy donors (characterized in
Supplemental Fig. 4) and analyzed PRMT5 expression by Western
blot from 0 to 7 d. We found that, similar to mouse T cells,
PRMT5 was upregulated 2.1-fold in Th1 cells and 1.9-fold in Th2
cells by 48 h postactivation (Fig. 2A, 2B), and was subsequently
downregulated to resting levels by 7 d postactivation. Importantly,
PRMT5 was also essential for the expansion of human T cells.
The PRMT5-selective inhibitor CMP5 preferentially suppressed
the proliferation of human Th1 cells over Th2 cells (43 versus 9%
inhibition, respectively, p , 0.05) (Fig. 2C, 2E), but it had min-
imal effects on cell death (Fig. 2D, 2F). To further evaluate the
increased sensitivity of Th1 cells over Th2 cells to PRMT5 inhi-
bition, we calculated the IC50 of human T cells when treated with
FIGURE 3. PRMT5 knockdown suppresses human T cell proliferation. (A) Human memory Th1 cells were activated with anti-CD3/CD28 for 48 h in the
presence of PRMT5 shRNA or scrambled (scr) control, and proliferation was monitored via [3H]thymidine incorporation. Proliferation relative to the
scrambled control condition (left panel) (data pooled from three independent experiments, n = 8). PRMT5, PRMT1, and PRMT7 expression measured by
Western blot and quantified using Image Studio software (right panels). ****p , 0.0001, Student t test. (B–D) Human Th1 and Th2 cells were activated as
in (A) in the presence of a Cy3-labeled scramble control siRNA, scrambled siRNA control (scr), or three PRMT5-specific siRNAs (si#1 targets the 59
untranslated region, si#2 targets exon 15, and si#3 targets exon 3). (B) Cy3siRNA+ cells (gated on CD4+ cells) were quantified by flow cytometry as a
measure of transfection efficiency. The transfection efficiency shown corresponds to Th1 cells. Equivalent efficiency was observed in Th2 cells. Prolif-
eration of human Th1 (C) and Th2 (D) cells was monitored by [3H]thymidine incorporation and expressed as a relative proliferation ratio to the NS
transfection control condition. PRMT5 and PRMT1 protein expression was measured by Western blot and quantified using Image Studio software. Protein
data are representative of three independent experiments and are pooled from three independent experiments (n = 9 for experiment shown). Plot error bars
show 6 SEM. *p , 0.05, ***p , 0.001, ****p , 0.0001, one-way ANOVA, followed by the Sidak multiple-comparison adjusted t test.
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CMP5 (Th1 IC50 = 26.9 mM versus Th2 IC50 = 31.6 mM) or
HLCL65 (Th1 IC50 = 5.7 mM versus Th2 IC50 = 14.3 mM) (Fig.
2G, 2H, Table I). To genetically validate a role for PRMT5 in
proliferation, we knocked down PRMT5 expression via shRNA
lentiviral transduction in human Th1 cells. PRMT5 shRNA par-
tially reduced PRMT5 protein levels (45%) but not other PRMTs
(PRMT1 and PRMT7), and it significantly decreased Th1 cell
proliferation (Fig. 3A). Although significant, the mild suppression
of proliferation could be explained by the low lentiviral trans-
duction efficiency expected in primary T cells, coupled with the
proliferative advantage of untransduced (i.e., PRMT5-sufficient)
cells. To increase efficiency, we used the Neon Transfection
System, which provided 70–90% transfection efficiency in our
primary human Th1/2 cell lines (Fig. 3B). Electroporation with
any of three PRMT5-specific siRNAs efficiently suppressed hu-
man Th1 and Th2 cell proliferation to a degree that correlated with
PRMT5 knockdown (Fig. 3C, 3D and a positive Pearson corre-
lation analysis of relative proliferation versus PRMT5 expression
in Th1 and Th2 cells, r = +0.7481, p , 0.0001, data not shown).
These results validate a role for PRMT5 in T cell–proliferative
responses. Interestingly, we observed that PRMT5 siRNA trans-
fection was accompanied by PRMT1 protein suppression, partic-
ularly in Th2 cells (Fig. 3C, 3D). Because the three siRNAs target
different areas in PRMT5 (59 untranslated region, exon 3, or exon
15), and each one was confirmed to lack complementarity with
PRMT1, it is unlikely that this is a direct effect of the siRNAs on
PRMT1 but rather is an indirect effect via PRMT5. Further studies
should aim to elucidate the significance of this finding. Overall,
these data indicate that PRMT5 is functionally conserved in
mouse and human T cells and plays a critical role in memory Th
cell reactivation and expansion.
PRMT5 expression is dependent upon TCR-induced NF-kB
signaling
The NF-kB pathway was associated with PRMT5 in hematologic
malignancies (56), but the pathways involved in PRMT5 expres-
sion in T cells are unknown. T cell reactivation activates several
signaling pathways, including the NF-kB pathway, leading to IL-2
production and proliferation. NF-kB transcription factors are kept
inactive in the cytoplasm through binding to the inhibitory Ik-B
subunits. Upon T cell activation, the Ik-B subunit is phosphory-
lated by IKKa and proteasomally degraded, allowing nuclear
FIGURE 4. T cell activation drives PRMT5 expres-
sion in an NF-kB–dependent manner. Differentiated
human Th1 (A) or Th2 (B) cells were reactivated on
anti-CD3/CD28 and treated with DMSO vehicle or
increasing amounts of the NF-kB pathway inhibitor
Bay11 for 8 h. Cells were lysed for Western blot
analysis of PRMT5 expression 48 h after initial acti-
vation. b-actin was used as a loading control. Relative
intensity quantification data are shown above a repre-
sentative blot quantified with Image Studio. Data are
representative of three independent experiments (n = 3
for experiment shown). Differentiated human Th1 (C)
and Th2 (D) cells were treated as described in (A) and
(B), and viability was monitored by trypan blue ex-
clusion. Data were pooled from three independent ex-
periments (n = 6). (E) Differentiated human Th1 cells
were treated as described in (A), and supernatants were
collected to analyze the concentration of IL-2 produc-
tion by ELISA. Data are representative of three inde-
pendent experiments (n = 2). Plot error bars show 6
SD. *p , 0.05, **p , 0.01, one-way ANOVA, fol-
lowed by the Sidak multiple-comparison adjusted t test.
n.d., not detected; n.s., not significant.
FIGURE 5. PRMT5 inhibition suppresses IL-2 production, and exoge-
nous IL-2 rescues CMP5-inhibited Th cell proliferation. IL-2 measured by
ELISA in supernatants of murine MBP TCR Th1 memory T cells (A) or
human Th1 cells (B) stimulated through the TCR at various time points in
the presence of CMP5 or vehicle control. Th2 cells are not shown because
they do not secrete IL-2. Data are from two or three independent experi-
ments (n = 4). **p , 0.01, ***p , 0.001, Student t test. Proliferation at
48 h, measured by [3H]thymidine incorporation, of mouse memory MBP
TCR-Tg Th1 (C) or human memory Th1 (D) T cells activated with anti-
CD3/CD28 in the presence of CMP5 or vehicle control and increasing
amounts of exogenous IL-2 (ng/ml). Data are representative of two or three
independent experiments (n = 3 for experiment shown). Plot error bars
show 6 SD. **p , 0.01, ANOVA, followed by the Sidak multiple-
comparison adjusted t test. n.s., not significant.
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translocation of NF-kB and activation of transcription (57). To test
whether NF-kB played a role in the upregulation of PRMT5 ex-
pression after TCR/CD28 costimulation, we treated human Th
cells with the IKK-a inhibitor Bay11 during the first 8 h of acti-
vation. After 48 h of TCR/CD28 stimulation, we observed a de-
crease in PRMT5 protein levels in healthy human donor Th1 cells
treated with Bay11 (Fig. 4A). In contrast, PRMT5 expression in
Th2 cells was less dependent on NF-kB signaling than was that
in Th1 cells, as evidenced by stable levels of PRMT5 expression
in Th2 cells treated with Bay11 (Fig. 4B). There were no differ-
ences in cell death with Bay11 treatment (Fig. 4C, 4D), indicating
that the changes in protein expression observed could not be
explained by cell death. As expected (58), NF-kB inhibition also
resulted in a 65% reduction in downstream cytokine IL-2 levels in
Th1 cells (Fig. 4E). These data are consistent with NF-kB sig-
naling promoting PRMT5 expression and IL-2 secretion during
TCR-mediated activation of Th1 and Th2 cells.
PRMT5 inhibition suppresses IL-2 secretion, and IL-2
restoration rescues T cell expansion
TCR-mediated activation of the NF-kB pathway promotes IL-2,
an important pro-proliferative T cell cytokine. We observed
reduced IL-2 with Bay11-mediated suppression of PRMT5, and
PRMT5 was linked to IL-2 production in Jurkat cancer T cells
(59). Therefore, we explored whether PRMT5 inhibition af-
fected IL-2 secretion in reactivated mouse or human Th1 and
Th2 memory T cells. Vehicle-treated mouse (Fig. 5A) and
human (Fig. 5B) Th1 cells secreted high levels of IL-2 at 24
and 48 h postactivation. In contrast, and as described previ-
ously for Th2 cells (60), no IL-2 was detected in Th2 cell su-
pernatants (data not shown). PRMT5 inhibition resulted in a
reduction in IL-2 secretion that ranged from 50 to 75% for
mouse Th1 cells and from 30 to 80% for human Th1 cells
(Fig. 5A, 5B). These data suggested that loss of IL-2 secretion
may contribute to the suppression of proliferation observed in
Th1 cells treated with PRMT5 inhibitors. To test whether the
blunted T cell proliferation observed after PRMT5 inhibition
could be rescued with IL-2 supplementation, memory Th1 cells
were activated with anti-CD3/CD28 in the presence or absence
of PRMT5 inhibitor and with increasing amounts of exogenous
IL-2. Doses from 1 to 20 ng/ml were chosen because it was
calculated that $10 ng/ml would be needed to restore the su-
pernatant IL-2 levels observed in the vehicle Th1 condition (as
in Fig. 5A). T cell proliferation was evaluated using a tritiated
thymidine–incorporation assay. Treatment with 25 mM CMP5
inhibited mouse Th1 cell proliferation by 91% (p , 0.001,
t test), and addition of IL-2 enhanced proliferation in the ve-
hicle condition, reaching a peak at 5 ng/ml (Fig. 5C). Addition
of IL-2 in the presence of PRMT5 inhibitor increased prolif-
eration in a dose-dependent manner, reaching 100% of the
control values at 10 ng/ml (Fig. 5C). Similarly, treatment with
25 mM CMP5 suppressed human Th1 cell proliferation by 50%,
and addition of exogenous IL-2 rescued proliferation (Fig. 5D).
The recovery of Th1 T cell proliferation with exogenous IL-2
indicates that IL-2 pathways are active downstream of IL-2R
and supports the notion that inhibition of IL-2 secretion by
PRMT5 inhibitors contributes to the observed reduction in Th1
T cell proliferation. However, additional mechanisms may play
a role in PRMT5 inhibitor–mediated suppression of prolifera-
tion, particularly in Th2 cells.
FIGURE 6. PRMT5 inhibition suppresses T cell responses and inflammation in the DTH model. (A) PRMT5 expression in spleens from naive mice or
from mice 5 or 10 d after immunization with OVA and CFA. Spleens were crushed under liquid nitrogen and lysed for Western blot analysis using b-actin as
a loading control. Data are representative of two independent experiments (data shown n = 3). (B) Schematic diagram of DTH model and treatment strategy.
Mice were sensitized to OVA with CFA/OVA immunization (flanks and tail base); mice were challenged in the footpad with OVA 7 and 14 d later, and
treated daily with 25 mg/kg PRMT5 inhibitor HLCL65 or DMSO i.p. between days 7 and 14. (C) Inflammation was evaluated on day 15 after initial
sensitization using calipers to quantify footpad swelling. (D) Day-15 splenocytes were activated in the presence or absence of OVA for 72 h, and pro-
liferation was monitored by [3H]thymidine incorporation. (E) Supernatants were collected from splenocytes isolated as described in (C), and IFN-g
production was measured by ELISA (n = 8). Data are representative of two independent experiments. Plot error bars show 6 SD. *p , 0.05, **p , 0.01,
***p , 0.001.
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FIGURE 7. PRMT5 inhibition suppresses in vivo inflammatory T cell responses and clinical disease in the EAE murine model of MS. (A) PRMT5
expression in mouse spleens from naive mice or from mice 5 or 10 d after immunization with CFA/MOG in the preclinical EAE phase. Spleens were
crushed under liquid nitrogen and lysed for Western blot analysis using b-actin as a loading control. Representative data of two independent experiments
are shown (n = 4). (B) Clinical EAE score in mice preventatively treated with DMSO vehicle or 25 mg/kg HLCL65 (every other day; arrows indicate
treatment) from days 0 to 9 after CFA/MOG immunization to induce EAE (n = 10). EAE score and the day of onset were monitored blindly daily. Mann–
Whitney test. Splenocytes (C) and brain/spinal cord mononuclear cells (D) were isolated from DMSO- or HLCL65-treated mice and activated in the
presence or absence of MOG35–55. (C) MOG-specific proliferation was monitored via [3H]thymidine incorporation (n = 3). ****p , 0.0001, one-way
ANOVA, followed by the Sidak multiple-comparison adjusted t test. (D) MOG-specific IL-17 production was measured by ELISA (n = 2 samples each
pooled from six individual mice per group). *p , 0.05, Student t test. (E) RNA was isolated from brains and spinal cord homogenates of DMSO- or
HLCL65-treated mice, and Tbx21 mRNA expression was measured by quantitative real-time PCR (Student t test, n = 2 or 3 per group). (F) EAE in mice
treated with DMSO vehicle or 25 mg/kg HLCL65 (every other day; arrows indicate treatment) starting on day 14 postimmunization, after EAE developed.
Mice were randomly assigned to either group (pretreatment average scores were 1.92 for DMSO and 1.96 for HLCL65) and blindly scored for EAE daily
(n = 6–7). Mann–Whitney test. *p , 0.05, **p , 0.01, ***p , 0.001. (G–I) Mice were immunized with CFA/MOG and treated with DMSO or 25 mg/kg
HLCL65 every other day starting 1 wk after immunization. Splenocytes were isolated from DMSO- or HLCL65-treated mice (Figure legend continues)
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PRMT5 inhibition suppresses in vivo OVA-induced DTH
inflammatory responses
The effectiveness of PRMT5 inhibitors at suppressing inflamma-
tory memory T cell responses suggested that they may be beneficial
in inflammatory or autoimmune disease. To test this, we used the
OVA-induced DTH mouse model and HLCL65, a more potent and
bioavailable derivative of CMP5 (Figs. 1H, 2H, Supplemental Fig.
2). First, we analyzed PRMT5 expression in the spleen of un-
treated mice after OVA immunization with CFA. We observed
that, at 10 d after immunization, PRMT5 expression was upreg-
ulated significantly in the spleen (Fig. 6A), suggesting that
PRMT5 expression is relevant to in vivo DTH immune responses.
In the DTH model (outlined in Fig. 6B), OVA immunization with
CFA induces an OVA-specific T cell response that causes footpad
inflammation in mice upon subsequent exposure to adjuvant-free
OVA and memory CD4+ T cell expansion. HLCL65 treatment
during the rechallenge period reduced footpad swelling, a measure
of inflammation, by 40% (p , 0.05, Fig. 6C). In addition, com-
pared with vehicle, HLCL65 treatment reduced OVA-specific
T cell proliferation by 36% (Fig. 6D) and IFN-g production by
70% (Fig. 6E). These data indicate that our novel PRMT5 in-
hibitor HLCL65 suppresses T cell–mediated responses and in-
flammation in vivo.
Prophylactic or therapeutic treatment with HLCL65
ameliorates EAE
The ability of PRMT5 inhibitors to suppress in vivo inflammatory
T cell responses could be beneficial in the autoimmune disease MS.
We observed that PRMT5 was upregulated in the spleen at 5 and
10 d after immunization with CFA/MOG (Fig. 7A), suggesting that
PRMT5 plays an important role in the immune response against
myelin Ags in vivo. In the MOG-induced murine EAE model,
T cell responses against this myelin Ag resulted in ascending
paralysis. We first tested whether short-term prophylactic
HLCL65 treatment (5 d, 25 mg/kg every other day starting at
immunization) could prevent EAE. Indeed, HLCL65 treatment
resulted in delayed disease onset (16.9 d for HLCL65-treated mice
versus 13.4 d for vehicle-treated mice) and a 33% reduction in
disease incidence compared with vehicle-treated mice (Table II).
Importantly, HLCL65-treated mice presented reduced EAE dis-
ease burden, as measured by the area under the curve (AUC),
compared with vehicle control (AUC HLCL65 versus vehicle: 2.1
versus 8.2, p = 0.016) (Fig. 7B, Table II). These clinical effects
were associated with reduced MOG-specific T cell–proliferative
responses (Fig. 7C), reduced CNS IL-17 production (Fig. 7D), and
a trend toward suppressed Tbet mRNA expression in the CNS
(Fig. 7E). With these promising results, we tested HLCL65 during
a therapeutically relevant window for MS patients (i.e., after
clinical signs had developed). HLCL65 treatment, beginning at
14 d after immunization (average score at treatment initiation =
2.7 out of 5), suppressed existing clinical signs of EAE, as mea-
sured by the total disease burden (AUC HLCL65 versus vehicle:
19.1 6 1.6 versus 27.31 6 3.1, Fig. 7F, Table III). This disease
suppression correlated with a reduction in MOG-specific T cell
proliferation in HLCL65-treated mice (Fig. 7G). Additionally,
inflammatory Th1 and Th17 responses were diminished in
HLCL65-treated mice (Fig. 7H, 7I). These data further support
that PRMT5 activity may be essential for T cell function and that
our novel PRMT5-selective inhibitors effectively suppress T cell–
mediated inflammation. Next, to test whether PRMT5 inhibitors
could suppress preformed encephalitogenic Th17 cells, spleno-
cytes from MBP TCR-Tg mice that had spontaneously developed
EAE (average score = 1.7) were activated with MBPAc1–11 in the
presence or absence of CMP5 and HLCL65. CMP5 treatment
significantly suppressed the frequency of pathogenic T-bet+
RORgt+ (61) (Fig. 7J) and classic IL-17+RORgt+ (Fig. 7K) Th17
cells in a dose-dependent manner. A similar dose-dependent de-
crease in pathogenic T-bet+IL-17+ Th17 cells (62) was apparent,
but it did not reach statistical significance (Fig. 7L). Similar re-
sults were observed with HLCL65 treatment (data not shown).
Taken together, these results indicate that PRMT5 promotes
pathogenic Th1 and Th17 cell responses that lead to inflammation
and autoimmunity.
Discussion
Memory T cell reactivation after Ag exposure rapidly induces
T cell proliferation and effector function. This process can be
beneficial, as in vaccination immunity, or deleterious, as in
perpetuation of pathogenic responses in autoimmunity. In this
article, we show by expression knockdown and pharmacologic
means that PRMT5, a methyltransferase that catalyzes SDM of
arginine residues in histones and other proteins, promotes the
activation and expansion of memory Th lymphocytes following
Ag re-exposure.
The first indications of a key role for arginine methylation
in lymphocyte activation originated from conditions and treatments
that inhibit all SAM-dependent methylation reactions (25, 26).
PRMTs were proposed to mediate some of these effects (29), but
the role of individual PRMTs in these processes remained unre-
solved. We found that Ag re-exposure in memory T cells upreg-
ulates PRMT5 expression as T cells proliferate and expand,
followed by a contraction phase in which PRMT5 expression is
progressively lost. The temporal link between PRMT5 expression
and proliferation, together with the observed inhibition of prolif-
eration upon selective PRMT5 inhibition, indicates that PRMT5
activity is necessary for TCR engagement–induced memory T cell
expansion. Th2 cell expansion was less dependent on PRMT5
activity than was that of Th1 cells. This difference was reproduced
in mouse and human Th cells, indicating that this is a conserved
difference that may impact human disease. However, differential
sensitivity to PRMT5 inhibition did not appear to stem from dif-
ferences in PRMT5 expression, which was equivalent in Th1 and
Th2 cells. It is possible that PRMT5 activity is lower in Th2 cells
than in Th1 cells as a result of the expression of type I methyl-
transferases, which compete with PRMT5 for substrates (63). This
difference offers the intriguing possibility that targeting
PRMT5 may modulate the Th1/Th2 balance defect observed in
autoimmune/inflammatory diseases, such as MS (12, 13).
The exact chain of events that leads to PRMT5 upregulation in
T cells is unclear. A link between the NF-kB pathway leading to
activation of the repressive p65/HDAC/Sp1 complex and loss
of PRMT5 targeting microRNA was reported in mantle cell
10 d after immunization and activated in the presence or absence of MOG. MOG-specific proliferation was monitored via [3H]thymidine incorporation (G), IFN-g+–
secreting cells were quantified by flow cytometry (gated on CD4+, CD44+ cells) (H), and IL-17 production was measured by ELISA (I). *p , 0.05, ***p , 0.001,
****p , 0.0001, one-way ANOVA, followed by the Sidak multiple-comparison adjusted t test. (J–L) Splenocytes were isolated from MBP TCR-Tg mice with
spontaneous EAE and activated with MBPAc1–11 in the presence of the indicated concentrations of the PRMT5 inhibitors CMP5 and HLCL65 or DMSO vehicle control
for 48 h. Frequencies of RORgt+T-bet+ (J), RORgt+IL-17+ (K), and IL-17+T-bet+ (L) T cells were quantified by intracellular flow cytometry on a CD4+CD44+ T cell
gate. One-way ANOVA, followed by Sidak multiple-comparison adjusted 1 test. Plot error bars show 6 SD. *p , 0.05. n.d., not detected; n.s. not significant.
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lymphoma (64). We also found previously that NF-kB inhibition
suppresses PRMT5 expression in EBV-transformed cells (51).
Because TCR engagement activates the NF-kB pathway in T cells,
a similar mechanism may regulate PRMT5 expression in T cells.
Indeed, blocking NF-kB signaling attenuated, but did not com-
pletely eliminate, PRMT5 expression in human Th1 cells. This
indicates that, although NF-kB is an important driver of PRMT5
expression in Th1 cells, other TCR-induced pathways play a more
significant role in regulating PRMT5 expression, especially in Th2
cells. TCR signaling cascades include the NFAT, ERK1/2, p38,
and JNK MAPK pathways. Interestingly, inhibitors of the p38 and
JNK MAPK pathways, but not the ERK1/2 pathway, were shown
to inhibit hypoxia-induced upregulation of PRMT5 in lung epi-
thelial cells (65). Although future studies are required to clarify
the extent to which these pathways affect PRMT5 upregulation in
T cells, NF-kB appears to play a major role in TCR-induced
PRMT5 expression in human Th1, but not Th2, cells. Addition-
ally, several studies showed that PRMT5 activates NF-kB sig-
naling through arginine methylation of p65 (56, 66–68),
suggesting that the NF-kB–PRMT5 signaling axis could involve a
positive-feedback loop. Additional studies are required to validate
this feedback loop and evaluate its role in T cells.
Several pathways downstream of TCR activation converge upon
activation of the IL-2 promoter to induce T cell proliferation (18,
19, 69). In this study, we found that IL-2 secretion is dependent on
PRMT5 activity and that addition of exogenous IL-2 to PRMT5
inhibitor–treated cells restored proliferation in Th1 cells. A role
for PRMT5 in IL-2 production is consistent with the observations
of Richard et al. (59); they reported that PRMT5 siRNA sup-
presses IL-2 secretion in the Jurkat cancer T cell line. This effect
is thought to be mediated by PRMT5-catalyzed arginine methyl-
ation on histones. In support of this hypothesis, symmetrically
dimethylated proteins associate with the IL-2 promoter after T cell
activation. In contrast, PRMT5 did not associate directly with the
IL-2 promoter. These data are consistent with PRMT5 indirectly
regulating IL-2 expression via SDM of target proteins. Although
the specific proteins that are methylated and bind to the IL-2
promoter remain to be defined, two proteins that form an IL-2
promoter–binding complex, NF-45 and NF-90, were proposed as
candidate targets (59). Another candidate is the TCR signaling
protein Vav-1, whose SDM was reported to promote IL-2 ex-
pression (70). Overall, our data point to IL-2 as one of the
mechanisms by which PRMT5 regulates proliferation in Th1 cells.
However, because we observed only a 60% reduction in IL-2
production, yet T cell proliferation is reduced by 90–95% when
treated with CMP5, it is likely that PRMT5 regulates proliferation
by several mechanisms. Because Th2 cells do not secrete large
amounts of IL-2, further studies are required to determine the
mechanism by which PRMT5 promotes Th2 cell proliferation.
Memory T cell responses play a critical role in chronic T cell–
mediated diseases, such as autoimmunity and allergy (71, 72). For
example, increased memory T cells were found in MS patients
with active disease, and they increased further during disease flare
(4), whereas the memory/naive T cell ratio diminishes in patients
responding to therapy (73). Importantly, inhibition of methyl-
transferases successfully suppresses T cell activation and estab-
lished clinical EAE and other inflammatory/autoimmune diseases
(25–28), but the lack of selectivity has prevented the development
of these treatments as therapy. Our data indicate that selective
PRMT5 inhibition reproduces the suppression of memory T cell
expansion observed with pan-methyltransferase inhibitors and
may be similarly effective in autoimmunity. Indeed, in vivo
treatment with PRMT5 inhibitors suppressed two models of
inflammatory/autoimmune disease: DTH footpad inflammation
and EAE CNS inflammation. Importantly, clinically established
EAE disease was responsive to PRMT5 inhibitor treatment. Our
data are consistent with T cells being a major target of PRMT5
inhibitors in EAE, although we cannot rule out a clinical contri-
bution of PRMT5 inhibition in non-T cells (CNS cells or APCs).
Effects on APCs could result in reduced TCR engagement and
T cell responses. However, in vitro experiments showed similar
suppressive effects when T cells are activated by anti-CD3/CD28
(Fig. 1E) or Ag-loaded APCs (Fig. 1C). In addition, HLCL65
treatment of EAE suppressed previously generated memory T cell
Table II. Prophylactic treatment with HLCL65 ameliorates EAE
Disease Parameter DMSO HLCL65 Change from DMSO p Value
EAE incidence (%) 90 57 233 n/a
Disease onset (d; mean 6 SD) 13.44 6 0.53 16.86 6 0.96 +3.42 d 0.0053
AUC (mean 6 SD) 8.214 6 1.58 2.143 6 1.41 26.071 0.0159
Score on day 17 (mean 6 SD) 2.3 6 0.37 1.0 6 0.48 21.3 0.048
Maximum score (mean 6 SD) 2.45 6 0.37 1.0 6 0.48 21.45 0.0285
n 10 7 n/a n/a
n/a, not applicable.
Table III. Therapeutic treatment with HLCL65 ameliorates EAE
Disease Parameter DMSO HLCL65 Change from DMSO p Value
EAE incidence (%): pretreatment 100 100 0 n/a
Disease onset (d): pretreatment (mean 6 SD) 11.67 6 0.49 12.43 6 0.37 +0.76 NS
Score on day 14 (mean 6 SD)a 2.7 6 0.40 2.7 6 0.40 0 NS
AUC: pretreatment (mean 6 SD) 4.60 6 1.15 3.91 6 0.91 20.69 NS
AUC: posttreatment (mean 6 SD) 27.31 6 3.13 19.11 6 1.61 28.2 0.0329
Maximum score: pretreatment (mean 6 SD) 2.7 6 0.40 2.7 6 0.40 0 NS
Maximum score: posttreatment (mean 6 SD) 3.88 6 0.38 2.93 6 0.44 20.95 0.0535
Score on day 22 (mean 6 SD) 3.5 6 0.51 2.14 6 0.19 21.36 0.0228
n 6 7 n/a n/a
aTreatment initiation occurred on day 14.
n/a, not applicable.
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responses, which are less dependent on APC costimulation. The
similarity in the suppression of proliferation and inflammatory
cytokines from in vitro and in vivo DTH/EAE studies is also con-
sistent with T cells being a major target. To investigate relevance to
human disease, we analyzed genome-wide association studies from
the International Multiple Sclerosis Genetics Consortium and the
Wellcome Trust Case Control Consortium. Interestingly, rs4410871
was identified as a high-frequency single-nucleotide polymorphism
in the MYC locus in MS patients (74). MYC was shown to be
upregulated after T cell activation (75) and to promote PRMT5
expression (37, 38). Taken together, these data suggest that PRMT5
could play a significant role in human disease.
In summary, this is the first report, to our knowledge, of the role
of PRMT5 expression in in vitro and in vivo nonmalignant T cell
responses. Our work identifies PRMT5 as an epigenetic modifier
enzyme that promotes memory Th cell expansion. Memory T cell
expansion of inflammatory Th1 cells and, to a lesser extent, Th2
cells, was dependent on PRMT5 activity. Finally, PRMT5 inhib-
itors suppressed T cell–mediated inflammatory and autoimmune
disease, suggesting that PRMT5 may be a promising therapeutic
target for autoimmune and other T cell–mediated diseases.
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